New Liver Cancer Therapy Resubmitted for FDA Review
Patients with advanced liver cancer may have a new first-line treatment option pending federal regulatory approval.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should regulatory bodies prioritize faster access to new cancer drugs despite potential safety uncertainties?
Elevar Therapeutics has resubmitted a New Drug Application to the FDA for a combination therapy to treat unresectable or metastatic hepatocellular carcinoma. The submission follows a previous regulatory rejection in July 2026.
Why it matters
This therapy aims to address the significant medical need for new first-line systemic treatments for advanced liver cancer. The company is working to bring this option to patients after receiving a Complete Response Letter earlier this year.
In the CARES-310 study, the combination therapy of rivoceranib and camrelizumab achieved a median overall survival of 23.8 months, compared to 15.2 months for patients treated with sorafenib.
The players
Elevar Therapeutics
A pharmaceutical subsidiary of HLB Co., Ltd. focused on developing cancer treatments for liver and other malignancies.
Hengrui Pharma
A pharmaceutical partner involved in the collaborative development and research of the combination therapy.
FDA
The United States agency responsible for regulating new drug applications and ensuring the safety and efficacy of medical treatments.
The details
The therapy uses a combination of rivoceranib and camrelizumab, which function as a systemic treatment for hepatocellular carcinoma. The drugs work together to inhibit tumor growth and modulate the immune response, offering a potential new strategy for unresectable or metastatic disease. Elevar Therapeutics, in collaboration with Hengrui Pharma, developed this approach to improve survival outcomes over the current standard of care.
Timeline
July 2026: FDA issued a Complete Response Letter for the initial application.
October 9, 2026: Elevar Therapeutics resubmitted the New Drug Application.
Health Landscape
The push for new systemic treatments reflects the ongoing evolution of liver cancer care, which often requires move-beyond traditional options like sorafenib. Findings from the CARES-310 study illustrate a broader trend of investigating combination immunotherapies to improve survival.
This resubmission represents a potential future milestone in advanced liver cancer treatment that remains under regulatory review. Patients interested in how these emerging clinical developments may eventually fit into their care plan should consult with their oncology team.
The takeaway
The resubmission of this combination therapy marks a step forward in the attempt to bring new systemic options to advanced liver cancer patients. Residents managing this condition should keep the study results in mind and discuss the potential for future therapeutic options with their oncologist.
Further reading
For more updates on emerging treatment developments, visit our Cancer section.
More information
Learn more about the company's research and development at the Elevar Therapeutics company information portal.
Live Poll
Should regulatory bodies prioritize faster access to new cancer drugs despite potential safety uncertainties?
